Abstract:De novo drug design with desired biological activities is crucial for developing novel therapeutics for patients. The drug development process is time- and resource-consuming, and it has a low probability of success. Recent advances in machine learning and deep learning technology have reduced the time and cost of the discovery process and therefore, improved pharmaceutical research and development. In this paper, we explore the combination of two rapidly developing fields with lead candidate discovery in the drug development process. First, artificial intelligence has already been demonstrated to successfully accelerate conventional drug design approaches. Second, quantum computing has demonstrated promising potential in different applications, such as quantum chemistry, combinatorial optimizations, and machine learning. This article explores hybrid quantum-classical generative adversarial networks (GAN) for small molecule discovery. We substituted each element of GAN with a variational quantum circuit (VQC) and demonstrated the quantum advantages in the small drug discovery. Utilizing a VQC in the noise generator of a GAN to generate small molecules achieves better physicochemical properties and performance in the goal-directed benchmark than the classical counterpart. Moreover, we demonstrate the potential of a VQC with only tens of learnable parameters in the generator of GAN to generate small molecules. We also demonstrate the quantum advantage of a VQC in the discriminator of GAN. In this hybrid model, the number of learnable parameters is significantly less than the classical ones, and it can still generate valid molecules. The hybrid model with only tens of training parameters in the quantum discriminator outperforms the MLP-based one in terms of both generated molecule properties and the achieved KL divergence. However, the hybrid quantum-classical GANs still face challenges in generating unique and valid molecules compared to their classical counterparts.

Enhancing molecular design efficiency: Uniting language models and generative networks with genetic algorithms

Adaptive language model training for molecular design

Advances in Deep Learning-Based 3D Molecular Generative Models

LS-MolGen: Ligand-and-Structure Dual-Driven Deep Reinforcement Learning for Target-Specific Molecular Generation Improves Binding Affinity and Novelty.

De novo drug design as GPT language modeling: large chemistry models with supervised and reinforcement learning

Machine learning-aided generative molecular design

Generative models for molecular discovery: Recent advances and challenges

LS-MolGen: Ligand-and-Structure Dual-driven Deep Reinforcement Learning for Target-specific Molecular Generation Improves Binding Affinity and Novelty

Relevant Applications of Generative Adversarial Networks in Drug Design and Discovery: Molecular De Novo Design, Dimensionality Reduction, and De Novo Peptide and Protein Design

Molecular design in drug discovery: a comprehensive review of deep generative models

Rethinking Molecular Design: Integrating Latent Variable and Auto-Regressive Models for Goal Directed Generation

Large Language Models as Molecular Design Engines

Genetic Algorithm-Based Receptor Ligand: A Genetic Algorithm-Guided Generative Model to Boost the Novelty and Drug-Likeness of Molecules in a Sampling Chemical Space.

Recent advances and application of generative adversarial networks in drug discovery, development, and targeting

Molecular Generative Adversarial Network with Multi-Property Optimization

Optimizing Drug Design by Merging Generative AI With Active Learning Frameworks

MedGAN: optimized generative adversarial network with graph convolutional networks for novel molecule design

Exploring the Advantages of Quantum Generative Adversarial Networks in Generative Chemistry

Probabilistic generative transformer language models for generative design of molecules

DrugGen: Advancing Drug Discovery with Large Language Models and Reinforcement Learning Feedback

When Molecular GAN Meets Byte-Pair Encoding